Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies. Lenzilumab has potential for use in combination with CAR-T and with checkpoint inhibitors across a range of cancers. Our next product candidate, ifabotuzumab is in the clinic for a rare brain cancer and could have applicability in other solid tumors.
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Director Interviews
Full interview: Humanigen plans Phase III clinical trial for lenzilumab to treat symptoms of coronavirus patients
Health
Full interview: Humanigen exploring potential therapeutic for lung damage arising from Coronavirus
